A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Stopped Sponsor decision following completion of Phase I part not driven by safety reason

Conditions

• Metastatic Cancer
• Soft Tissue Sarcoma
• Merkel Cell Carcinoma
• Melanoma
• Triple Negative Breast Cancer
• Non Small Cell Lung Cancer

Interventions

• BIOLOGICAL: BT-001
• DRUG: Pembrolizumab [KEYTRUDA®]

Sponsor

Transgene

Collaborators

• [object Object]
• [object Object]